DMX-200 receives Orphan Drug Designation in Japan
Filed with ASX · · 3 pages · English
Story so far
Earlier from Dimerix
- Appendix 4E and 2025 Annual Report
- Dimerix receives 1st Development Milestone payment from FUSO
- ACTION3 Clinical Trial Milestone Recruitment Update
- 1st ACTION3 site in Japan activated and milestone triggered
- Successful planned IDMC review of ACTION3 trial
Later from Dimerix
- Successful PARASOL Collaboration Data Analysis Outcome
- Successful Completion of Planned IDMC Review
- DMX-200 ACTION3 Phase 3 Trial Completes Recruitment
- BioMarin to acquire Dimerix US Partner, Amicus Therapeutics
- Quarterly Appendix 4C and Activities Report
Follow Dimerix into a list and get an email when it puts out news.
Follow Dimerix